Dividend hunters, rejoice! Two healthcare stocks just defied industry norms and announced dividend hikes, making them rare gems in a sector not known for generous payouts. But here's where it gets interesting: these aren't your typical healthcare players. Let's dive into why Bristol Myers Squibb and Zoetis are turning heads and wallets alike.
While the pre-holiday season is usually a quiet time for dividend increases, these two companies decided to end the year with a bang. And this is the part most people miss: healthcare, often overlooked for its dividend potential, is hiding some surprisingly reliable payers.
Bristol Myers Squibb: A Dividend Powerhouse with a 94-Year Streak
This pharmaceutical giant isn't just a household name in medicine; it's a dividend champion. With an impressive 94-year history of paying dividends and 17 consecutive years of increases, Bristol Myers Squibb recently sweetened the deal with a 1.6% hike to $0.63 per share quarterly. But what's their secret sauce?
The company's success lies in its dual-pronged approach: a 'growth' portfolio featuring patented blockbuster drugs like the cancer treatment Opdivo, and a 'legacy' lineup including the blood-thinner Eliquis. While legacy sales dipped 12% in Q3, the growth segment soared 18%, driving overall revenue up 3% to $12.2 billion. This balance, coupled with robust free cash flow exceeding $5.9 billion in Q3, ensures the dividend remains secure and attractive, currently yielding around 5%.
Zoetis: The Animal Kingdom's Dividend Darling
Zoetis takes a different path, dominating the animal health market with a 20% global share. Since its spin-off from Pfizer in 2013, it's consistently rewarded shareholders with quarterly dividends, recently upping the ante by 6% to $0.53 per share. But what makes this niche so lucrative?
The pet health market is booming, with 66% of U.S. households now owning pets, up from 56% in 1988. Zoetis capitalizes on this trend, generating two-thirds of its sales from pet medications. Meanwhile, its livestock business benefits from rising global protein demand. With revenue climbing from $6.7 billion in 2020 to nearly $9.3 billion in 2024, and net income jumping from $1.6 billion to almost $2.5 billion, Zoetis is a growth story with a dividend kicker, currently yielding 1.8%.
Controversial Question: Are These Dividends Sustainable?
While both companies boast strong fundamentals, the healthcare sector is notoriously volatile. Bristol Myers Squibb's reliance on patent-protected drugs raises questions about long-term growth once exclusivity ends. Zoetis, though riding the pet boom, faces competition and regulatory hurdles in animal health. Are these dividends a safe bet, or is the market overestimating their longevity? Share your thoughts below—do you see these stocks as reliable income generators, or is there a risk we're overlooking?
